Symbols / REGN Stock $635.45 +1.07% Regeneron Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
REGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Leonard S. Schleifer M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 66.62B
Enterprise Value 58.60B
Income 4.42B
Sales 14.92B
FCF (ttm) 3.27B
Book/sh 308.32
Cash/sh 86.04
Employees 15,343
Insider 10d —
IPO Apr 02, 1991
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 8.74%
P/E 15.50
Forward P/E 11.82
PEG 1.09
P/S 4.47
P/B 2.06
P/C —
EV/EBITDA 13.37
EV/Sales 3.93
Quick Ratio 2.84
Current Ratio 3.56
Debt/Eq 8.61
LT Debt/Eq —
EPS (ttm) 40.99
EPS next Y 53.77
EPS Growth -7.20%
Revenue Growth 19.00%
EPS Gr Q/Q -10.10%
Rev Gr Q/Q —
Earnings (next) 2026-07-30
Earnings (prior) 2026-04-29
ROA 6.13%
ROE 14.55%
ROIC —
Gross Margin 43.89%
Oper. Margin 20.66%
Profit Margin 29.65%
Shs Outstand 103.02M
Shs Float 97.67M
Insider Own 2.03%
Instit Own 92.18%
Short Float 2.80%
Short Ratio 3.55
Short Interest 2.78M
52W High 821.11
vs 52W High -22.61%
52W Low 476.49
vs 52W Low 33.36%
Beta 0.24
Impl. Vol. 46.56%
Rel Volume 1.17
Avg Volume 831.08K
Volume 975.51K
Target (mean) $833.31
Tgt Median $852.50
Tgt Low $641.00
Tgt High $1,000.00
# Analysts 28
Recom Buy
Prev Close $628.73
Price $635.45
Change 1.07%
About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$833.31
Mean price target
2. Current target
$635.45
Latest analyst target
3. DCF / Fair value
$571.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$635.45
Low
$641.00
High
$1000.00
Mean
$833.31

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-19 main Canaccord Genuity Buy → Buy $875
2026-05-18 main BMO Capital Outperform → Outperform $730
2026-05-18 main Truist Securities Buy → Buy $778
2026-05-18 main JP Morgan Overweight → Overweight $850
2026-05-18 main Piper Sandler Overweight → Overweight $855
2026-05-18 main Wells Fargo Equal-Weight → Equal-Weight $700
2026-05-18 main RBC Capital Sector Perform → Sector Perform $707
2026-05-18 down Citigroup Buy → Neutral $700
2026-05-18 down Leerink Partners Outperform → Market Perform $641
2026-05-01 main Guggenheim Buy → Buy $995
2026-04-30 main RBC Capital Sector Perform → Sector Perform $762
2026-04-30 main Barclays Overweight → Overweight $917
2026-04-30 main Truist Securities Buy → Buy $796
2026-04-30 main Wells Fargo Equal-Weight → Equal-Weight $800
2026-04-23 main TD Cowen Buy → Buy $960
2026-04-23 reit Cantor Fitzgerald Overweight → Overweight $800
2026-04-10 main Morgan Stanley Equal-Weight → Equal-Weight $796
2026-04-08 main Bernstein Outperform → Outperform $921
2026-03-31 main Truist Securities Buy → Buy $801
2026-03-06 init Barclays — → Overweight $923
News
RSS: Latest REGN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-01 RYAN ARTHUR F Director — 100 $701.76 $70,524
2026-04-01 RYAN ARTHUR F Director — 100 $771.32 $77,727
2026-03-02 RYAN ARTHUR F Director — 100 $777.46 $78,550
2026-02-19 ZOGHBI HUDA Y Director — 1,638 $774.68 $1,279,812
2026-02-19 ZOGHBI HUDA Y Director — 1,638 $376.69 $617,018
2026-02-09 PITOFSKY JASON Officer — 2,036 $775.95 $1,585,058
2026-02-09 RYAN ARTHUR F Director — 100 $775.63 $77,853
2026-02-09 PITOFSKY JASON Officer — 1,000 $492.00 $492,000
2026-01-07 BASSLER BONNIE L Director — 1,500 $800.00 $1,200,000
2026-01-07 BASSLER BONNIE L Director — 1,500 $374.12 $561,180
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
14,342.90
+0.99%
14,202.00
+8.27%
13,117.20
+7.76%
12,172.90
Operating Revenue
13,640.30
-0.34%
13,687.00
+8.79%
12,581.10
+6.55%
11,807.80
Cost Of Revenue
2,100.70
+6.61%
1,970.50
+8.52%
1,815.80
+16.37%
1,560.40
Reconciled Cost Of Revenue
2,100.70
+6.61%
1,970.50
+8.52%
1,815.80
+16.37%
1,560.40
Gross Profit
12,242.20
+0.09%
12,231.50
+8.23%
11,301.40
+6.49%
10,612.50
Operating Expense
8,540.20
+3.63%
8,240.80
+13.60%
7,254.30
+23.51%
5,873.60
Research And Development
5,850.20
+11.79%
5,233.00
+13.14%
4,625.10
+20.21%
3,847.60
Selling General And Administration
2,700.00
-8.61%
2,954.40
+12.28%
2,631.30
+24.36%
2,115.90
Other Operating Expenses
-10.00
-118.73%
53.40
+2642.86%
-2.10
+97.66%
-89.90
Total Expenses
10,640.90
+4.21%
10,211.30
+12.58%
9,070.10
+22.01%
7,434.00
Operating Income
3,702.00
-7.23%
3,990.70
-1.39%
4,047.10
-14.60%
4,738.90
Total Operating Income As Reported
3,577.90
-10.34%
3,990.70
-1.39%
4,047.10
-14.60%
4,738.90
EBITDA
5,818.20
+9.41%
5,318.00
+13.31%
4,693.30
-10.77%
5,259.60
Normalized EBITDA
4,996.20
-5.74%
5,300.70
+3.01%
5,145.80
-6.51%
5,504.30
Reconciled Depreciation
543.70
+12.59%
482.90
+14.70%
421.00
+23.32%
341.40
EBIT
5,274.50
+9.09%
4,835.10
+13.17%
4,272.30
-13.13%
4,918.20
Total Unusual Items
822.00
+4651.45%
17.30
+103.82%
-452.50
-84.92%
-244.70
Total Unusual Items Excluding Goodwill
822.00
+4651.45%
17.30
+103.82%
-452.50
-84.92%
-244.70
Special Income Charges
-124.10
-22.87%
-101.00
+45.73%
-186.10
+27.05%
-255.10
Other Special Charges
124.10
+22.87%
101.00
-45.73%
186.10
-27.05%
255.10
Restructuring And Mergern Acquisition
—
—
186.10
-27.05%
255.10
Net Income
4,504.90
+2.09%
4,412.60
+11.61%
3,953.60
-8.87%
4,338.40
Pretax Income
5,230.70
+9.43%
4,779.90
+13.83%
4,199.30
-13.57%
4,858.80
Net Non Operating Interest Income Expense
673.00
+2.56%
656.20
+55.17%
422.90
+319.96%
100.70
Interest Expense Non Operating
43.80
-20.65%
55.20
-24.38%
73.00
+22.90%
59.40
Net Interest Income
673.00
+2.56%
656.20
+55.17%
422.90
+319.96%
100.70
Interest Expense
43.80
-20.65%
55.20
-24.38%
73.00
+22.90%
59.40
Interest Income Non Operating
716.80
+0.76%
711.40
+43.46%
495.90
+209.74%
160.10
Interest Income
716.80
+0.76%
711.40
+43.46%
495.90
+209.74%
160.10
Other Income Expense
855.70
+543.38%
133.00
+149.13%
-270.70
-1509.90%
19.20
Other Non Operating Income Expenses
33.70
+129.25%
14.70
+441.86%
-4.30
-148.86%
8.80
Gain On Sale Of Security
946.10
+699.75%
118.30
+144.41%
-266.40
-2661.54%
10.40
Tax Provision
725.80
+97.60%
367.30
+49.49%
245.70
-52.79%
520.40
Tax Rate For Calcs
0.00
+80.57%
0.00
+30.24%
0.00
-44.86%
0.00
Tax Effect Of Unusual Items
114.06
+8479.87%
1.33
+104.98%
-26.70
-1.97%
-26.18
Net Income Including Noncontrolling Interests
4,504.90
+2.09%
4,412.60
+11.61%
3,953.60
-8.87%
4,338.40
Net Income From Continuing Operation Net Minority Interest
4,504.90
+2.09%
4,412.60
+11.61%
3,953.60
-8.87%
4,338.40
Net Income From Continuing And Discontinued Operation
4,504.90
+2.09%
4,412.60
+11.61%
3,953.60
-8.87%
4,338.40
Net Income Continuous Operations
4,504.90
+2.09%
4,412.60
+11.61%
3,953.60
-8.87%
4,338.40
Normalized Income
3,796.96
-13.64%
4,396.63
+0.39%
4,379.40
-3.90%
4,556.92
Net Income Common Stockholders
4,504.90
+2.09%
4,412.60
+11.61%
3,953.60
-8.87%
4,338.40
Diluted EPS
41.48
+8.19%
38.34
+10.27%
34.77
-9.03%
38.22
Basic EPS
43.07
+5.31%
40.90
+10.39%
37.05
-8.54%
40.51
Basic Average Shares
104.60
-3.06%
107.90
+1.12%
106.70
-0.37%
107.10
Diluted Average Shares
108.60
-5.65%
115.10
+1.23%
113.70
+0.18%
113.50
Diluted NI Availto Com Stockholders
4,504.90
+2.09%
4,412.60
+11.61%
3,953.60
-8.87%
4,338.40
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
40,558.70
+7.41%
37,759.40
+14.15%
33,080.20
+13.23%
29,214.50
Current Assets
18,021.90
-3.42%
18,660.90
-4.20%
19,479.20
+22.63%
15,884.10
Cash Cash Equivalents And Short Term Investments
8,605.20
-4.52%
9,012.50
-16.90%
10,844.80
+40.07%
7,742.30
Cash And Cash Equivalents
3,118.10
+25.32%
2,488.20
-8.86%
2,730.00
-12.10%
3,105.90
Other Short Term Investments
5,487.10
-15.90%
6,524.30
-19.60%
8,114.80
+75.02%
4,636.40
Receivables
5,741.10
-7.58%
6,211.90
+9.61%
5,667.30
+6.35%
5,328.70
Accounts Receivable
5,741.10
-7.58%
6,211.90
+9.61%
5,667.30
+6.35%
5,328.70
Inventory
3,200.80
+3.68%
3,087.30
+19.64%
2,580.50
+7.44%
2,401.90
Raw Materials
641.50
-27.06%
879.50
+11.43%
789.30
-3.56%
818.40
Work In Process
1,641.60
+22.30%
1,342.30
+19.66%
1,121.80
+16.48%
963.10
Finished Goods
190.20
+36.05%
139.80
-5.09%
147.30
+49.39%
98.60
Prepaid Assets
—
—
—
411.20
Current Deferred Assets
—
—
—
521.80
Other Current Assets
474.80
+35.97%
349.20
-9.67%
386.60
-5.98%
411.20
Total Non Current Assets
22,536.80
+18.00%
19,098.50
+40.42%
13,601.00
+2.03%
13,330.40
Net PPE
5,120.40
+11.32%
4,599.70
+10.93%
4,146.40
+10.19%
3,763.00
Gross PPE
7,734.70
+12.32%
6,886.60
+12.43%
6,125.20
+12.76%
5,432.20
Accumulated Depreciation
-2,614.30
-14.32%
-2,286.90
-15.57%
-1,978.80
-18.55%
-1,669.20
Properties
0.00
0.00
0.00
0.00
Land And Improvements
278.80
-3.26%
288.20
+1.80%
283.10
+7.03%
264.50
Buildings And Improvements
3,105.90
+20.70%
2,573.20
+6.19%
2,423.10
+6.74%
2,270.00
Machinery Furniture Equipment
741.70
+13.31%
654.60
+17.82%
555.60
+13.95%
487.60
Construction In Progress
1,890.20
+9.79%
1,721.60
+28.00%
1,345.00
+37.17%
980.50
Other Properties
1,543.70
+3.29%
1,494.50
+7.95%
1,384.50
+5.26%
1,315.30
Leases
174.40
+12.88%
154.50
+15.38%
133.90
+17.15%
114.30
Goodwill And Other Intangible Assets
1,257.40
+9.47%
1,148.60
+10.59%
1,038.60
+13.45%
915.50
Other Intangible Assets
1,257.40
+9.47%
1,148.60
+10.59%
1,038.60
+13.45%
915.50
Investments And Advances
10,260.60
+15.29%
8,900.10
+64.92%
5,396.50
-18.13%
6,591.80
Non Current Deferred Assets
4,077.20
+23.03%
3,314.10
+28.68%
2,575.40
+49.41%
1,723.70
Non Current Deferred Taxes Assets
4,077.20
+23.03%
3,314.10
+28.68%
2,575.40
+49.41%
1,723.70
Other Non Current Assets
1,821.20
+60.32%
1,136.00
+155.80%
444.10
+32.02%
336.40
Total Liabilities Net Minority Interest
9,301.80
+10.66%
8,405.80
+18.27%
7,107.10
+8.50%
6,550.50
Current Liabilities
4,368.40
+10.75%
3,944.30
+15.22%
3,423.40
+8.98%
3,141.30
Payables And Accrued Expenses
3,815.40
+15.04%
3,316.60
+11.88%
2,964.50
+11.31%
2,663.40
Payables
1,290.30
+28.68%
1,002.70
+62.17%
618.30
+4.94%
589.20
Accounts Payable
939.00
+18.94%
789.50
+30.15%
606.60
+2.95%
589.20
Current Accrued Expenses
2,525.10
+9.13%
2,313.90
-1.38%
2,346.20
+13.11%
2,074.20
Total Tax Payable
351.30
+64.77%
213.20
+1722.22%
11.70
+3800.00%
0.30
Income Tax Payable
351.30
+64.77%
213.20
+1722.22%
11.70
+3800.00%
0.30
Current Debt And Capital Lease Obligation
—
—
—
—
Current Capital Lease Obligation
—
—
—
0.00
Current Deferred Liabilities
553.00
-11.90%
627.70
+36.78%
458.90
-3.98%
477.90
Current Deferred Revenue
553.00
-11.90%
627.70
+36.78%
458.90
-3.98%
477.90
Total Non Current Liabilities Net Minority Interest
4,933.40
+10.58%
4,461.50
+21.11%
3,683.70
+8.05%
3,409.20
Long Term Debt And Capital Lease Obligation
2,705.90
+0.06%
2,704.40
+0.06%
2,702.90
+0.06%
2,701.40
Long Term Debt
1,985.90
+0.08%
1,984.40
+0.08%
1,982.90
+0.08%
1,981.40
Long Term Capital Lease Obligation
720.00
+0.00%
720.00
+0.00%
720.00
+0.00%
720.00
Non Current Deferred Liabilities
208.70
+12.39%
185.70
+46.57%
126.70
+81.52%
69.80
Non Current Deferred Revenue
208.70
+12.39%
185.70
+46.57%
126.70
+81.52%
69.80
Other Non Current Liabilities
2,018.80
+28.47%
1,571.40
+83.98%
854.10
+33.87%
638.00
Stockholders Equity
31,256.90
+6.48%
29,353.60
+13.02%
25,973.10
+14.60%
22,664.00
Common Stock Equity
31,256.90
+6.48%
29,353.60
+13.02%
25,973.10
+14.60%
22,664.00
Capital Stock
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Common Stock
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
139.42
+1.16%
137.82
+2.15%
134.92
+2.06%
132.20
Ordinary Shares Number
105.72
-3.56%
109.62
+0.18%
109.42
-0.17%
109.60
Treasury Shares Number
33.70
+19.50%
28.20
+10.59%
25.50
+12.83%
22.60
Additional Paid In Capital
13,995.00
+8.86%
12,855.90
+13.23%
11,354.00
+14.12%
9,949.30
Retained Earnings
35,797.10
+13.02%
31,672.90
+16.19%
27,260.30
+16.96%
23,306.70
Gains Losses Not Affecting Retained Earnings
77.50
+1081.01%
-7.90
+90.23%
-80.90
+66.12%
-238.80
Treasury Stock
18,612.80
+22.72%
15,167.40
+20.76%
12,560.40
+21.32%
10,353.30
Other Equity Adjustments
77.50
+1081.01%
-7.90
+90.23%
-80.90
+66.12%
-238.80
Total Equity Gross Minority Interest
31,256.90
+6.48%
29,353.60
+13.02%
25,973.10
+14.60%
22,664.00
Total Capitalization
33,242.80
+6.08%
31,338.00
+12.10%
27,956.00
+13.43%
24,645.40
Working Capital
13,653.50
-7.22%
14,716.60
-8.34%
16,055.80
+26.00%
12,742.80
Invested Capital
33,242.80
+6.08%
31,338.00
+12.10%
27,956.00
+13.43%
24,645.40
Total Debt
2,705.90
+0.06%
2,704.40
+0.06%
2,702.90
+0.06%
2,701.40
Capital Lease Obligations
720.00
+0.00%
720.00
+0.00%
720.00
+0.00%
720.00
Net Tangible Assets
29,999.50
+6.36%
28,205.00
+13.12%
24,934.50
+14.65%
21,748.50
Tangible Book Value
29,999.50
+6.36%
28,205.00
+13.12%
24,934.50
+14.65%
21,748.50
Available For Sale Securities
10,260.60
+15.29%
8,900.10
+64.92%
5,396.50
-18.13%
6,591.80
Dueto Related Parties Current
—
—
—
10.50
Investmentin Financial Assets
10,260.60
+15.29%
8,900.10
+64.92%
5,396.50
-18.13%
6,591.80
Other Inventories
727.50
+0.25%
725.70
+39.00%
522.10
+0.06%
521.80
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
4,978.90
+12.63%
4,420.50
-3.78%
4,594.00
-8.39%
5,014.90
Cash Flow From Continuing Operating Activities
4,978.90
+12.63%
4,420.50
-3.78%
4,594.00
-8.39%
5,014.90
Net Income From Continuing Operations
4,504.90
+2.09%
4,412.60
+11.61%
3,953.60
-8.87%
4,338.40
Depreciation Amortization Depletion
543.70
+12.59%
482.90
+14.70%
421.00
+23.32%
341.40
Depreciation
—
354.10
+7.69%
328.80
+8.19%
303.90
Amortization Cash Flow
—
128.90
+39.80%
92.20
+145.21%
37.60
Depreciation And Amortization
543.70
+12.59%
482.90
+14.70%
421.00
+23.32%
341.40
Amortization Of Intangibles
—
128.90
+39.80%
92.20
+145.21%
37.60
Other Non Cash Items
135.50
+275.35%
36.10
+36200.00%
-0.10
-100.02%
563.00
Stock Based Compensation
993.70
+1.11%
982.80
+11.05%
885.00
+22.07%
725.00
Deferred Tax
-785.40
-3.71%
-757.30
+9.61%
-837.80
-12.25%
-746.40
Deferred Income Tax
-785.40
-3.71%
-757.30
+9.61%
-837.80
-12.25%
-746.40
Operating Gains Losses
-946.10
-699.75%
-118.30
-144.41%
266.40
+623.91%
36.80
Gain Loss On Investment Securities
-946.10
-699.75%
-118.30
-144.41%
266.40
+623.91%
36.80
Change In Working Capital
532.60
+186.14%
-618.30
-557.07%
-94.10
+61.32%
-243.30
Change In Receivables
498.10
+189.91%
-554.00
-63.52%
-338.80
-147.87%
707.80
Changes In Account Receivables
498.10
+189.91%
-554.00
-63.52%
-338.80
-147.87%
707.80
Change In Inventory
-275.30
+55.58%
-619.70
-128.08%
-271.70
+60.99%
-696.50
Change In Prepaid Assets
-375.30
+7.90%
-407.50
-239.30%
-120.10
+19.18%
-148.60
Change In Payables And Accrued Expense
736.80
+0.23%
735.10
+22.80%
598.60
+532.51%
-138.40
Change In Payable
736.80
+0.23%
735.10
+22.80%
598.60
+532.51%
-138.40
Change In Account Payable
736.80
+0.23%
735.10
+22.80%
598.60
+532.51%
-138.40
Change In Other Working Capital
-51.70
-122.70%
227.80
+501.06%
37.90
+16.98%
32.40
Investing Cash Flow
-629.10
+74.51%
-2,468.10
+22.51%
-3,185.10
+15.84%
-3,784.60
Cash Flow From Continuing Investing Activities
-629.10
+74.51%
-2,468.10
+22.51%
-3,185.10
+15.84%
-3,784.60
Net PPE Purchase And Sale
0.00
-100.00%
20.10
0.00
0.00
Sale Of PPE
0.00
-100.00%
20.10
0.00
0.00
Capital Expenditure
-1,213.70
-37.67%
-881.60
+4.84%
-926.40
+42.71%
-1,616.90
Capital Expenditure Reported
-898.40
-18.85%
-755.90
-5.19%
-718.60
-21.78%
-590.10
Net Investment Purchase And Sale
587.90
+136.97%
-1,590.10
+27.85%
-2,203.80
-13.75%
-1,937.40
Purchase Of Investment
-10,958.30
+34.06%
-16,617.40
-42.69%
-11,646.00
-55.53%
-7,487.90
Sale Of Investment
11,546.20
-23.17%
15,027.30
+59.15%
9,442.20
+70.11%
5,550.50
Net Business Purchase And Sale
-3.30
+80.00%
-16.50
+69.95%
-54.90
+76.16%
-230.30
Purchase Of Business
-3.30
+80.00%
-16.50
+69.95%
-54.90
+76.16%
-230.30
Net Intangibles Purchase And Sale
-315.30
-150.84%
-125.70
+39.51%
-207.80
+79.76%
-1,026.80
Purchase Of Intangibles
-315.30
-150.84%
-125.70
+39.51%
-207.80
+79.76%
-1,026.80
Net Other Investing Changes
—
—
—
-230.30
Financing Cash Flow
-3,715.40
-68.84%
-2,200.50
-22.93%
-1,790.10
-77.41%
-1,009.00
Cash Flow From Continuing Financing Activities
-3,715.40
-68.84%
-2,200.50
-22.93%
-1,790.10
-77.41%
-1,009.00
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
-3,334.80
-53.88%
-2,167.10
-21.06%
-1,790.10
-77.41%
-1,009.00
Common Stock Payments
-3,970.70
-9.31%
-3,632.40
-23.74%
-2,935.60
-16.10%
-2,528.50
Common Stock Dividend Paid
-370.30
0.00
0.00
—
Cash Dividends Paid
-370.30
0.00
0.00
—
Repurchase Of Capital Stock
-3,970.70
-9.31%
-3,632.40
-23.74%
-2,935.60
-16.10%
-2,528.50
Net Other Financing Charges
-10.30
+69.16%
-33.40
—
—
Changes In Cash
634.40
+355.70%
-248.10
+34.92%
-381.20
-272.25%
221.30
Effect Of Exchange Rate Changes
0.30
+142.86%
-0.70
-75.00%
-0.40
0.00
Beginning Cash Position
2,489.00
-9.09%
2,737.80
-12.23%
3,119.40
+7.64%
2,898.10
End Cash Position
3,123.70
+25.50%
2,489.00
-9.09%
2,737.80
-12.23%
3,119.40
Free Cash Flow
3,765.20
+6.39%
3,538.90
-3.51%
3,667.60
+7.93%
3,398.00
Interest Paid Supplemental Data
41.60
-20.91%
52.60
-28.04%
73.10
+36.13%
53.70
Income Tax Paid Supplemental Data
—
743.00
-14.63%
870.30
-42.07%
1,502.40
Common Stock Issuance
635.90
-56.60%
1,465.30
+27.92%
1,145.50
-24.61%
1,519.50
Issuance Of Capital Stock
635.90
-56.60%
1,465.30
+27.92%
1,145.50
-24.61%
1,519.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category